ConductScience.org, home

Gene · 4103

MAGEA4: MAGE family member A4

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. MAGEA4: MAGE family member A4. Genes, record 4103. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4103

On this page

Gene

Symbol
MAGEA4
HGNC
Name
MAGE family member A4
HGNC
NCBI Gene ID
4103
NCBI Gene
HGNC ID
HGNC:6802
HGNC
Ensembl
ENSG00000147381
NCBI Gene
Aliases
CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B, MGC21336
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P43358Melanoma-associated antigen 43179Ensembl, GeneID, HGNC

Source UniProt

Patents183

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4810517 A12026-09-2323P43358Espacenet
JP 2026120534 A2026-07-2236P43358Espacenet
EP 4772538 A12026-07-0848P43358Espacenet
JP 2026511570 A2026-04-1423P43358Espacenet
JP 2026509604 A2026-03-1925P43358Espacenet
JP 2026004568 A2026-01-1453045P43358Espacenet
JP 2026004568 A2026-01-1453046P43358Espacenet
JP 2026004568 A2026-01-1453047P43358Espacenet
JP 2026004568 A2026-01-1453048P43358Espacenet
JP 2026004568 A2026-01-1453049P43358Espacenet

1 to 10 of 183

See all 183 patents

Drugs1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismAction
AFAMITRESGENE AUTOLEUCELCHEMBL4802254Melanoma-associated antigen 4 binding agentBINDING AGENT

Source ChEMBL

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants479

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleMAGEA4 papersNewest fiscal year
P30CA016672Cancer Center Support Grant152025
P50CA126752SPORE in Lymphoma102025
P30CA008748Cancer Center Support Grant82025
P30CA125123Baylor College of Medicine Cancer Center - Cancer Center Support Grant82025
P30CA016056Roswell Park Cancer Center Support Grant72025
P30ES010126UNC Center for Environmental Health and Susceptibility52025
P30CA016086Cancer Center Support Grant42025
ZIABC010985Gene therapy of cancer42025
P50CA159981Roswell Park Ovarian Cancer SPORE32025
T32ES007126Pre- and Postdoctoral Training in Toxicology32025

1 to 10 of 479Source NIH's project files

See all 479 nih grants

Papers1,316

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Top advances of the year in autologous cellular therapy in melanoma and solid tumors.Cancer202642734903PubTator, text miningPubMed
MAGEA4 promotes gastric cancer progression by inducing chromosomal instability through the STAU1/c-Myc axis.Cancer Genet202642673884PubTator, text miningPubMed
Adult Undifferentiated Embryonal Sarcoma of the Liver with Spontaneous Tumor Rupture and Comprehensive Molecular Profiling: A Case Report.Case Rep Oncol202642524507PubTator, text miningPubMed
The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.Hum Vaccin Immunother202642517272PubTator, text miningPubMed
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.J Immunother Cancer202642476725PubTator, text miningPubMed
Established and Emerging Less Invasive Biomarkers and Technologies for Lung Cancer Screening: Puerto Rican Context.Onco (Basel)202642389670PubTator, text miningPubMed
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.Nat Med202642321382PubTator, text miningPubMed
Screening of Demethylation-related Biomarkers and Exploration of Regulatory Mechanisms in Esophageal Cancer Patients Based on Machine Learning and Mendelian Randomization.Curr Cancer Drug Targets202642261153PubTator, text miningPubMed
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.Nat Med202642219399PubTator, text miningPubMed
The Landscape of Clinical Trials for TCR-T Cell Therapy.Am J Clin Oncol202642184246PubTator, text miningPubMed

1 to 10 of 1,316

See all 1,316 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/4103

GET https://conductscience.org/api/genes/v1/4103/patents?page=2